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Telomerase activity is associated with over 90% of human breast cancers and is necessary for continued tumor cell growth, making it an ideal target for inhibition therapy. However, pharmacologic inhibitors of telomerase have not been as effective as expected. As such, our objective here is to identify novel telomerase interacting proteins and define their functional relationship to telomerase in order to provide additional targets for telomerase inhibition in breast cancer. In addition to the results that we reported in previous annual reports concerning telomere binding proteins and chaperone interactions, we have found that telomerase is a modified protein, capable of being ubiquinated and sumolylated and is able to be degraded via both nuclear and cytoplasmic mechanisms. We show that inhibition of the Hsp90 chaperone results in telomerase degradation in the nucleus, but association of wild-type telomerase with a dominant-negative version results in cytoplasmic degradation. We show that telomerase is associated with the proteosome in both the nucleus and cytoplasm and that this alternative regulation of telomerase is key for functionally blocking its activity as an adjuvant target for chemotherapeutics for breast cancer.
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Introduction
Telomerase is a cellular reverse transcriptase that is associated with over 90% of human breast cancers and is composed of 2 integral components, an RNA template (hTR -human Telomerase RNA) and a catalytic polymerase (hTERT -human TElomerase Reverse Transcriptase) (Weinrich et al 1997) . Telomerase is an obvious chemotherapeutic target (Shay and Bacchetti, 1997) . Telomerase activity requires its two core components, hTERT and hTR, to be assembled into a functionally active enzyme by the Hsp90 chaperone complex (Holt et. al., 1999) . We have previously demonstrated that chaperones are essential for optimal telomerase assembly in vitro (Holt et. al., 1999) and that Hsp90 itself remains associated with the functional telomerase complex (Forsythe et. al., 2001 ) (see Figure 1) .
In a human cancer progression model, increased assembly of telomerase by chaperones, including Hsp90, has been shown to correlate with cancer progression, which is defined as increased aggressiveness in vivo (Akalin et. al., 2001 ). These findings indicate that increased expression of the Hsp90 chaperone complex with the associated activation of telomerase activity may be important steps in cancer formation (Holt et. al., 1999; Akalin et. al., 2001 ). While telomerase in cancer progression has been widely studied (reviewed by Shay and Bacchetti, 1997) , the role of chaperones in carcinogenesis and their interplay between telomerase and its substrate, the telomere, are less well defined. 
Body
Rationale: The overall goal of this proposal has been to identify mammary-specific telomerase interacting proteins that will serve as targets for direct and indirect inhibition of telomerase and determine the consequences of these interactions during breast cancer progression. Given some of the limitations of telomerase reagents, we have slightly altered our goals to include the regulation of telomerase through its interaction with the hsp90 chaperone complex and the association of telomerase with the proteosome machinery. The experiments discussed in this final report will allow further understanding and characterization of the mechanisms of telomerase/telomere structure and function as it relates specifically to breast cancer and will facilitate innovative techniques and protocols for early detection and treatment of breast cancer.
Objective #1: Define the regulation of telomerase by the identification of mammary-specific telomerase interacting proteins using a proteomic approach.
The previous report indicated problems with hTERT antibodies (still a problem) and that we have been assessing proteins that were bound to hsp90 in breast tumor cells as an alternative to finding telomerase interactors specific for mammary-derived cells. We have found that the hsp90 chaperone complex binds specifically to telomeres and to the telomere binding protein, TRF-2. We continue with this project in an attempt to show a functional significance for this interaction and to determine if chaperones interact with other telomere binding proteins.
During the final funding phase of the proposal, we have found that telomerase is associated with the proteosome machinery, suggesting that telomerase is readily degraded, depending on the state of the cell. As such, we have discovered that telomerase is degraded in the nucleus and in the cytoplasm, using proteolytic mechanisms in both areas of the cell. Nuclear degradation is understudied and represents an important, novel mechanism of telomerase regulation.
Nuclear Degradation
Initial characterization of the MCF-7/GFP-hTERT cell line was performed in terms of Western blot, confocal fluorescence, growth assay and telomere length assays to assess molecular weight, localization, and in vivo activity. GFP-hTERT was shown to be expressed at it's predicted molecular weight of 160 kD with increased telomerase activity and telomere lengths (not shown). The elevated activity and telomere lengths did not affect the growth rate such that the population doubling rate of 0.9 pd per day is similar to control. The nuclear localization and mostly nucleolar exclusion of GFPhTERT is similar to what has been observed in the literature (Wong et al., 2002) 
When treated with a variety of drugs, the GFP-hTERT cells showed a pronounced effect after Radicicol (RAD) treatment, which is an hsp90 inhibitor (Compton et al., 2006) . Subsequent drug experiments were done using RAD because chronic blockage of hsp90 in cancer cells causes a transient decline in telomerase activity coupled with reactive oxygen-induced telomere shortening (Compton et al., 2006) . To further understand the effect of Hsp90 inhibition, acute and chronic treatments were analyzed for fluorescence and telomere length. Acute exposure caused an almost complete loss of fluorescence within 2 hours (Fig.2 middle picture and quantitation). After 2 days, the fluorescence GFP signal had not recovered but telomere lengths remained the same (data not shown). Even so, the cells continue to divide but at a reduced growth rate of 0.6 PD per day during treatment. With continued hsp90 inhibition on a 2-day cycle, the 8 th day analysis showed a recovery of fluorescence, and after 12 and 24 days, the fluorescent signal was almost fully recovered despite continued presence of Radicicol (not shown). Like many Hsp90 client proteins, telomerase is degraded after Hsp90 inhibition. Specifically, Kim et al showed that telomerase was ubiquinated by MKRN1 then degraded by the proteasome (Kim et al., 2005) . Thus, we initially postulated that a destabilized telomerase due to Hsp90 inhibition caused its nuclear exportation followed by cytoplasmic degradation. We envisioned a model in which the destabilized telomerase is phosphorylated by a Src kinase at Tyrosine 707 to signal its exportation through the 14-3-3 sigma/Exportin path, followed by ubiquination with an E3 ligase and degradation by the 26S proteasome in the cytoplasm. However, our preliminary data shows that inhibition of Exportin and hsp90 still caused the same loss of fluorescence intensity as compared to Hsp90 inhibition alone (Fig. 2) . The combination treatment of RAD and proteasome inhibitor, MG132, remains fluorescent and nucleoplasmic, suggesting that degradation of telomerase occurs in the nucleus. In fact, telomerase appears to accumulate around the nucleoli into protein aggregates (Fig. 2 bottom left panel). These "aggresomes" have been described for other proteins and consist of chaperones, ubiquinated proteins and the 26S proteasome (Johnson et al., 1998) . Western analysis shows that the protein levels of GFP-hTERT correspond to the quantitation of the loss of fluorescence after Hsp90 inhibition (compare top right panel for the quantification with the bottom right panel for the Western blot).
Immunoprecipitation followed by Western analysis of the combination treatment (RAD and MG132) showed less degradation as compared to RAD alone, yet increased ubiquination as compared to control (Fig. 3) . We also tested to determine if hTERT colocalized with 26S proteosome within the nucleus using immunofluorescence, and found that after treatment with RAD, GFP-hTERT and nuclear 26S were co-localized in RADtreated cells after inhibition of degradation with the MG132 proteosome inhibitor (Fig. 4) . Taken together, these data suggest that Hsp90 inhibition causes telomerase to be ubiquinated then degraded by proteasomes located within the nucleus. Review of the literature shows the existence of a nuclear ubiquitin/proteasome pathway with all of the appropriate components as well as a few substrates and functions (von Mikecz, 2006 Figure 3 . Ubiquination and degradation products of GFPhTERT after 2 hours of treatment. Cells were lysed and immunoprecipitated for GFP followed by Western for ubiquitin. Radicicol treatment shows high levels of degradation as compared to the other conditions. MG132 alone shows a slightly higher level of ubiquination as expected due to inhibition of normal GFPhTERT turnover. The band at 55 kD represents the IgG from IP. CTL is untreated control. Separate lanes on the same exposed film were spliced together to cut out unrelated experimental data. 
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Cytoplasmic Degradation
Recent data from our lab suggested that a dominant-negative form of hTERT caused inhibition of telomerase activity, shortening of telomerase, and perhaps degradation in a variety of cell lines. In order to follow the degradation of hTERT, we created a GFP-DNhTERT fusion protein and characterized cells expressing this construct (Fig. 5) . We find that DN-hTERT induces telomere shortening and is partially degraded, as there is no significant difference in mRNA levels (Fig. 5, RT-PCR panel) . Treatment of cells with the proteosome inhibitor, MG132, prevents degradation of DN-hTERT (Fig. 6 , top and bottom panels), while the nuclear exportation inhibitor, LMB, prevents export of DNhTERT to the cytoplasm (retained in the nucleus), subsequently preventing degradation (Fig. 6, top panel) . Together, these data suggest that DN-hTERT is exported from the nucleus to the cytoplasm for degradation. To more accurately assess whether DN-hTERT can physically cause the translocation of wild-type hTERT to the cytoplasm for degradation, we dually infected GFP-hTERT and the DN-hTERT without the GFP fusion. Thus, if DN-hTERT "drags" wild-type hTERT out of the nucleus, we should see GFP-hTERT in the cytoplasm. Figure 7 shows that normally, GFP-hTERT is cytoplasmic (in the absence of DN-hTERT), but when DNhTERT is also expressed, the wild-type GFP-hTERT is predominantly cytoplasmic, indicating that one of the mechanisms for the dominant-negative effect of telomerase is translocation of wild-type to the cytoplasm, reducing its telomere maintenance function. (Fig. 8B) and degraded (Fig. 8A) , presumably in the cytoplasm (see Fig. 7 , with no effect on mRNA levels (Fig. 8A, RT-PCR) . Collectively, our data indicate that DN-hTERT functions, at least partially, to inhibit the wild-type hTERT by translocation to the cytoplasm for degradation via a ubiquitin-mediated mechanism. Key Research Accomplishments 1-cell culture models of the GFP/telomerase fusion over-expression have been created, in mammary-related cell lines. 2-specific mechanisms related to telomerase stability and degradation have been identified and explored. 3-identification of a novel chaperone-mediated mechanism for degrading telomerase in the nucleus. 
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Development of Cell Lines
We are have generated a variety of cell lines using the GFP-hTERT fusion protein (Wong et al., 2002) to be used to understand telomerase trafficking and regulation. 
Conclusions
Overall, the use of specific telomerase antibodies has been limited, which in turn limits our ability to identify telomerase interacting proteins using immunoprecipitation. As a result of this setback, we have cloned and expressed a fusion protein of telomerase using the GFP tag, which provides us with antibodies and visualization of the telomerase enzyme. We have shown that telomerase is regulated via 2 distinct mechanisms related to hsp90-mediated degradation: in the nucleus and in the cytoplasm. As a result, we have expanded our proposal to defining the mechanisms of telomerase stability and cellular regulation, in addition to the discovery of telomerase associated proteins specific for breast cancer. Understanding the regulatory mechanisms related to telomeres and telomerase in mammary-related cells will facilitate the development of improved therapeutic strategies specifically targeting breast tumor cells. 
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